News archive
Showing 683 results
March 2014
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age… -
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
January 2014
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Patient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients… -
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
December 2013
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4)-- Presentations include findings that 19 of… -
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
October 2013
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
Every 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted… -
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
September 2013
-
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
Study result signals potential kidney benefit with RLX030;1 future studies will further explore this impact Kidney dysfunction affects approximately 30 percent of US heart failure… -
Media Release
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
June 2013
-
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6… -
Media Release
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease